Detalles de la búsqueda
1.
Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD.
Int J Neuropsychopharmacol
; 26(3): 198-206, 2023 03 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36525338
2.
Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality.
BMC Psychiatry
; 23(1): 587, 2023 08 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37568081
3.
The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder.
Depress Anxiety
; 38(11): 1120-1130, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34293233
4.
Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
Int J Neuropsychopharmacol
; 23(7): 426-433, 2020 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-32270176
5.
Patient-reported outcomes in major depressive disorder with suicidal ideation: a real-world data analysis using PatientsLikeMe platform.
BMC Psychiatry
; 20(1): 384, 2020 07 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32703173
6.
Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
J Psychopharmacol
; 37(8): 836-844, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36218274
7.
Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
CNS Drugs
; 37(8): 715-723, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37558912
8.
Predictors of response and remission in patients with treatment-resistant depression: A post hoc pooled analysis of two acute trials of esketamine nasal spray.
Psychiatry Res
; 323: 115165, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37019044
9.
Treatment patterns and decision drivers to discharge patients with depression hospitalised for acute suicidal ideation in Europe.
J Affect Disord
; 311: 614-621, 2022 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35598749
10.
Use of Clinical Global Impressions-Severity (CGI-S) to Assess Response to Antidepressant Treatment in Patients with Treatment-Resistant Depression.
Neuropsychiatr Dis Treat
; 18: 1127-1132, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35707064
11.
Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.
Int J Methods Psychiatr Res
; 31(4): e1927, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35749277
12.
Patient profiles, initial hospital encounter characteristics, and hospital re-encounters of patients with a hospital emergency department visit or inpatient admission for major depressive disorder.
J Med Econ
; 25(1): 172-181, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35048772
13.
Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials.
Neuropsychiatr Dis Treat
; 17: 3459-3470, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34880615
14.
Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled Randomized, Controlled Trials.
Neuropsychiatr Dis Treat
; 17: 2347-2357, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34290505
15.
Comments to Drs. Bahji, Vazquez, and Zarate.
J Affect Disord
; 283: 262-264, 2021 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33571795
16.
Cardiac risk at the onset of treatment in patients treated with benzodiazepines and clozapine.
Eur Psychiatry
; 17(7): 419-20, 2002 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-12547310
Resultados
1 -
16
de 16
1
Próxima >
>>